Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 15:01:09 GMT 2023
by
admin
on
Sat Dec 16 15:01:09 GMT 2023
|
Protein Sub Type | |
Sequence Origin | HUMAN |
Sequence Type | COMPLETE |
Record UNII |
66UL4XJJ3X
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
P43119
Created by
admin on Sat Dec 16 15:01:10 GMT 2023 , Edited by admin on Sat Dec 16 15:01:10 GMT 2023
|
PRIMARY | |||
|
66UL4XJJ3X
Created by
admin on Sat Dec 16 15:01:10 GMT 2023 , Edited by admin on Sat Dec 16 15:01:10 GMT 2023
|
PRIMARY |
From | To |
---|---|
1_5 | 1_165 |
1_92 | 1_170 |
Glycosylation Type | HUMAN |
Glycosylation Link Type | Site |
---|---|
N | 1_7 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
ACT-333679 is 37-fold more potent than selexipag towards prostacyclin IP receptor.
IC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
BINDING
IC50
|
||
|
AGONIST -> TARGET |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT | CHEMICAL |
|
||||
Molecular Formula | CHEMICAL |
|